Open AccessBLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia–reperfusion injury
Author(s) -
Vince C de Hoog,
Sandra M. Bovens,
Saskia C.A. de Jager,
Ben J. van Middelaar,
Amerik van Duijvenvoorde,
Pieter A. Doevendans,
Gerard Pasterkamp,
Dominique P.V. de Kleijn,
Leo Timmers
Publication year - 2015
Publication title -
cardiovascular research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.774
H-Index - 219
eISSN - 1755-3245
pISSN - 0008-6363
DOI - 10.1093/cvr/cvv224
Subject(s) - medicine , myocardial infarction , reperfusion injury , apoptosis , inflammation , ischemia , cardiology , antagonist , ejection fraction , ligation , left coronary artery , immune system , pharmacology , receptor , immunology , chemistry , heart failure , biochemistry
Restoration of coronary blood flow is crucial in the treatment of acute myocardial infarction. Reperfusion, however, induces ischaemia-reperfusion (IR) injury, which further deteriorates myocardial function. The innate immune system plays an important role in this process, mediating rapid influx of immune cells into the reperfused myocardium. Leukotriene B4 is an important leucocyte chemoattractant, performing its actions through binding to its specific receptor BLT1. We hypothesized that treatment with LSN2792613, a selective BLT1 antagonist, reduces infarct size (IS) in a mouse model of myocardial IR injury.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom